Southern Micro Medicine: Revenue of 3.191 billion yuan in 2025, a year-on-year increase of 3.05% in net profit.

Nanwei Medical announced that in 2025, the company achieved a total operating income of 3,190,931.9 million yuan, a year-on-year increase of 15.81%; net profit attributable to owners of the parent company was 570,114 million yuan, a year-on-year increase of 3.05%; non-recurring net profit was 557.1235 million yuan, a year-on-year increase of 2.40%. At the end of the reporting period, total assets were 543,404 million yuan, an increase of 13.69% compared to the beginning of the period; equity attributable to owners of the parent company was 410,853.2 million yuan, an increase of 7.38% compared to the beginning of the period. Revenue growth was driven by overseas business and new products, while profit growth was impacted by centralized procurement, destocking channels, increased investment expenses, and exchange rate fluctuations.